Globus Medical (NYSE:GMED) Shares Down 6.5% – What’s Next?

Globus Medical, Inc. (NYSE:GMED)’s share price fell 6.5% on Tuesday . The stock traded as low as $76.88 and last traded at $78.46. 192,185 shares were traded during mid-day trading, a decline of 87% from the average session volume of 1,434,343 shares. The stock had previously closed at $83.94.

Analysts Set New Price Targets

A number of research analysts have commented on GMED shares. Zacks Research raised Globus Medical from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 3rd. Needham & Company LLC boosted their price target on Globus Medical from $114.00 to $117.00 and gave the company a “buy” rating in a report on Friday, May 8th. Piper Sandler dropped their price target on Globus Medical from $115.00 to $100.00 and set an “overweight” rating on the stock in a research report on Monday, June 15th. Weiss Ratings restated a “hold (c+)” rating on shares of Globus Medical in a research note on Wednesday, April 15th. Finally, Wall Street Zen downgraded shares of Globus Medical from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, Globus Medical currently has an average rating of “Moderate Buy” and a consensus price target of $105.00.

Globus Medical Stock Down 7.3%

The company has a market capitalization of $10.57 billion, a P/E ratio of 18.11, a PEG ratio of 1.78 and a beta of 0.95. The business has a 50 day simple moving average of $83.39 and a 200-day simple moving average of $87.37.

Globus Medical (NYSE:GMED) last announced its quarterly earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.92 by $0.20. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. The company had revenue of $759.85 million during the quarter, compared to the consensus estimate of $740.35 million. During the same quarter in the previous year, the company posted $0.68 earnings per share. The company’s revenue for the quarter was up 27.0% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. Equities analysts forecast that Globus Medical, Inc. will post 4.74 EPS for the current fiscal year.

Insider Buying and Selling at Globus Medical

In other news, Director David D. Davidar sold 25,000 shares of Globus Medical stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the sale, the director owned 510,175 shares of the company’s stock, valued at approximately $41,201,733. The trade was a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 18.38% of the company’s stock.

Institutional Trading of Globus Medical

Several large investors have recently added to or reduced their stakes in GMED. Pacer Advisors Inc. boosted its position in Globus Medical by 3.6% during the 1st quarter. Pacer Advisors Inc. now owns 34,365 shares of the medical device company’s stock worth $2,961,000 after acquiring an additional 1,188 shares during the period. Defilade Capital Management L.P. grew its stake in shares of Globus Medical by 32.6% in the first quarter. Defilade Capital Management L.P. now owns 354,350 shares of the medical device company’s stock worth $30,531,000 after purchasing an additional 87,138 shares in the last quarter. NewEdge Advisors LLC increased its holdings in shares of Globus Medical by 20.0% during the first quarter. NewEdge Advisors LLC now owns 30,540 shares of the medical device company’s stock valued at $2,631,000 after purchasing an additional 5,091 shares during the period. Glenmede Trust Co. NA increased its holdings in shares of Globus Medical by 22.8% during the first quarter. Glenmede Trust Co. NA now owns 225,446 shares of the medical device company’s stock valued at $19,424,000 after purchasing an additional 41,801 shares during the period. Finally, Summitry LLC raised its stake in shares of Globus Medical by 2.6% during the first quarter. Summitry LLC now owns 8,205 shares of the medical device company’s stock valued at $707,000 after purchasing an additional 211 shares in the last quarter. 95.16% of the stock is currently owned by institutional investors and hedge funds.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.